Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to investigate the effect of roflumilast (APTA-2217) on lung function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily. The study duration consists of a baseline period (4 weeks) and a treatment period (24 weeks). The study will provide further data on safety, tolerability, and effectiveness of roflumilast.

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Mitsubishi Tanabe Pharma Corporation

Criteria

Main inclusion criteria:

• Patients with chronic obstructive pulmonary disease

• Current smoker or ex-smoker

• 30 to 80% of predicted FEV1 after inhalation of short acting beta stimulant

Main exclusion criteria:

• Patients with poorly controlled COPD

• Patients who need for long-term oxygen therapy

• Patients who have concurrent respiratory diseases such as asthma, diffuse panbronchiolitis, congenital sinobronchial syndrome, bronchiolitis obliterans, bronchiectasis, active tuberculosis, pneumoconiosis, pulmonary lymph vascular myoma, which are considered to affect the evaluation